Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study

QR Code

Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study

Context: We previously designed, developed and characterized a novel microencapsulated formulation as a platform for the targeted delivery of Probucol (PB) in an animal model of Type 2 Diabetes. Objective: The objective of this study is to optimize this platform by incorporating Chenodeoxycholic aci...

Full description

Bibliographic Details
Main Authors:	Mooranian, A., Negrulj, R., Mikov, M., Golocorbin-Kon, S., Arfuso, Frank, Al-Salami, Hani
Format:	Journal Article
Published:	Taylor and Francis Ltd 2015
Online Access:	http://hdl.handle.net/20.500.11937/44153

Similar Items

Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol
by: Mooranian, Armin, et al.
Published: (2014)

The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study
by: Mooranian, A., et al.
Published: (2015)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
by: Mooranian, Armin, et al.
Published: (2015)

An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
by: Mooranian, Armin, et al.
Published: (2014)

An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques
by: Mooranian, Armin, et al.
Published: (2019)

Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid
by: Mooranian, A., et al.
Published: (2018)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment (vol 32, pg 151, 2014)
by: Mooranian, A., et al.
Published: (2015)

Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses
by: Mooranian, A., et al.
Published: (2018)

An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations
by: Mooranian, A., et al.
Published: (2015)

Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration
by: Mamo, J., et al.
Published: (2018)

Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes
by: Mooranian, Armin, et al.
Published: (2014)

Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine ß-cell Survival and the Inflammatory Response
by: Mooranian, A., et al.
Published: (2016)

Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes
by: Negrulj, R., et al.
Published: (2015)

Novel artificial cell microencapsulation of probucol and bile acids in diabetes mellitus
by: Mooranian, Armin
Published: (2018)

Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
by: Mooranian, Armin, et al.
Published: (2014)

Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic ß-cell line
by: Mooranian, A., et al.
Published: (2015)

Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes
by: Mooranian, Armin, et al.
Published: (2018)

Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics
by: Mooranian, Armin, et al.
Published: (2014)

Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
by: Mooranian, Armin, et al.
Published: (2014)

Alginate-combined cholic acid increased insulin secretion of microencapsulated mouse cloned pancreatic ß cells
by: Mooranian, A., et al.
Published: (2017)

Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects
by: Mathavan, S., et al.
Published: (2017)

High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect
by: Golocorbin-Kon, S., et al.
Published: (2017)

The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes
by: Mathavan, S., et al.
Published: (2015)

Viability and topographical analysis of microencapsulated ß-cells exposed to a biotransformed tertiary bile acid: An ex vivo study
by: Mooranian, Armin, et al.
Published: (2016)

Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System
by: Negrulj, Rebecca, et al.
Published: (2013)

The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects
by: Mooranian, Armin, et al.
Published: (2018)

Alginate-deoxycholic Acid Interaction and Its Impact on Pancreatic ?-Cells and Insulin Secretion and Potential Treatment of Type 1 Diabetes
by: Mooranian, Armin, et al.
Published: (2016)

The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable ß-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies.
by: Mooranian, A., et al.
Published: (2015)

Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance:
by: Al-Salami, Hani, et al.
Published: (2016)

Probiotics applications in autoimmune diseases
by: Al-Salami, Hani, et al.
Published: (2012)

Dried Blood Spot: Utilizing Dry Blood For Pharmacokinetic Investigations—An Old Method with Great Future for Therapeutic Drug Monitoring
by: Maksimovic, V., et al.
Published: (2017)

Advanced bile acid-based multi-compartmental microencapsulated pancreatic ß-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.
by: Mooranian, A., et al.
Published: (2014)

Probucol prevents blood–brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet
by: Mamo, John, et al.
Published: (2018)

New biotechnological microencapsulating methodology utilizing individualized gradient-screened jet laminar flow techniques for pancreatic ß-cell delivery: bile acids support cell energy-generating mechanisms
by: Mooranian, A., et al.
Published: (2017)

Dried blood spot: Utilising dry blood for pharmacokinetic investigations - An old method with great future for therapeutic drug monitoring
by: Golocorbin-Kon, S., et al.
Published: (2018)

Pharmacokinetic and Drug Absorption Profiles of the Anti-Hyperglycaemic Agent Gliclazide in Oral Tissue-Targeted Microcapsules in Rats
by: Jovic, Jelena, et al.
Published: (2020)

Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid
by: Mathavan, S., et al.
Published: (2018)

Influence of the concentration of chenodeoxycholic acid on the performance of the N719 dye
by: Najm, A. S., et al.
Published: (2022)

Microencapsulation of black seed oil in alginate beads for stability and taste masking
by: Alkhatib, Hamzeh, et al.
Published: (2020)

Sodium alginate decreases the permeability of intestinal mucus
by: Mackie, Alan R., et al.
Published: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5c2teaa7an79a9tmgukpoic111